Today's Date
A Phase I Study: Safety Of RG2077 (CTLA4-IgG4m) In Patients With Relapsing-Remitting Multiple Sclerosis
(
)
ITN Protocol #:
ITN006AI
Branded Name:
ClinicalTrials.Gov ID:
NCT00076934Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Completed
Summary:
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS.
